Boston Scientific Corporation $BSX Stake Boosted by AQR Capital Management LLC

Key Points

• AQR Capital Management LLC increased its stake in Boston Scientific Corporation by 26.7%, acquiring an additional 243,893 shares, bringing its total ownership to approximately $114.4 million.
• Over 89% of Boston Scientific's stock is owned by institutional investors, indicating strong market confidence in the company.
• Boston Scientific reported a 22.8% year-over-year revenue growth for the last quarter, with earnings per share exceeding analyst expectations, now projecting $0.700-0.720 EPS for Q3 2025.

AQR Capital Management LLC lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 26.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,155,829 shares of the medical equipment provider's stock after purchasing an additional 243,893 shares during the quarter. AQR Capital Management LLC owned about 0.08% of Boston Scientific worth $114,427,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. GAMMA Investing LLC raised its position in shares of Boston Scientific by 11,720.3% during the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after acquiring an additional 2,556,078 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock worth $968,172,000 after acquiring an additional 1,709,461 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Boston Scientific by 161.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after acquiring an additional 1,536,663 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Trading Up 0.9%

Shares of BSX stock traded up $0.92 during trading hours on Monday, hitting $108.14. 7,454,396 shares of the company were exchanged, compared to its average volume of 7,464,520. The firm has a market cap of $160.23 billion, a PE ratio of 64.37, a PEG ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $108.94. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a fifty day moving average of $104.77 and a 200 day moving average of $102.15.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Needham & Company LLC restated a "buy" rating and set a $115.00 price target on shares of Boston Scientific in a research note on Wednesday, May 28th. Morgan Stanley lifted their target price on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Truist Financial lifted their target price on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Robert W. Baird upped their price objective on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Finally, UBS Group increased their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $117.79.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.